AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 91 min read$NEOG

Nassif Mikheal purchased $6K of NEOG (indirect holdings)

Nassif Mikheal (CEO) purchased 505 indirectly-held shares of NEOGEN CORP (NEOG) at $11.95 on 2026-10-09.

Original reporting
SEC EDGAR · Nassif Mikheal
Published Oct 9, 2026, 11:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 11:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NEOG
Neutral
medium confidence
Mentioned
$NEOG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NEOGNeutralLow
01

Why it matters

The filing provides a fresh, primary‑source data point on insider activity but the monetary size is minimal.

02

Market read

A small insider purchase with limited trading relevance; unlikely to affect price materially.

03

What to watch

If the CEO holds a larger undisclosed stake, this small buy might be part of a larger accumulation strategy.

Relevance 3/10Novelty 3/10Timing: same‑day filing

Background

Form 4 filings disclose insider trades and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$NEOGNeutralMedium confidence
Context

CEO Nassif Mikheal bought 505 shares of NEOG at $11.95 in an open‑market purchase filed on 2026‑10‑09.

Expected impact

minor upward pressure as the market prices in the insider buy

Evidence & confidence

The transaction is a primary Form 4 filing, but the amount is trivial relative to market cap, so any price effect is expected to be modest.

Market effects

Sector

No material impact on the broader biotech sector.

Regional

Limited to U.S. markets; no regional ripple.

Global

Not globally relevant.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Company
    Neogen Corp

    US‑listed biotech firm (ticker NEOG).

  • Person
    Nassif Mikheal

    CEO of Neogen Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NEOG insider trading history →

Related articles

OCT 8
$NEOGMedAI 8/10

Neogen’s Earnings Call Signals Confident Growth Path

Neogen reported Q1 revenue of $222.8M, up 8.1% core, with Food Safety and Animal Safety segments driving growth. Management raised fiscal 2027 guidance to $885M-$890M sales and adjusted EBITDA of $181M-$183M, citing strong demand and operational improvements. The company plans to use genomics divestiture proceeds for debt reduction, aiming for net leverage below 3x.

tipranks.com3 min
OCT 7
$NEOGLow

Neogen Outlines Strategy for Growth, Innovation and Margin Expan

Neogen Corporation (NEOG) outlined its growth strategy at its 2026 Investor Day, targeting high-single-digit to low-double-digit revenue growth, high-50% adjusted gross margin, and 30% adjusted EBITDA margin by FY2031. The company plans to increase R&D investment by 50% in FY2027, aiming for $100M in incremental revenue from new products by FY2031. Neogen also highlighted its data platform, Neogen Analytics, as a key driver of recurring revenue and customer retention.

gurufocus.com3 min